PM CDT at the ASCO Annual MeetingMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...

Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external committee approved advancing its cancer drug trial to the next dosing cohort.

Pasithea Therapeutics Corp. announced that its Vice President of Business Development, Mathew Lazarus, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference ...

MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company ...

Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) shares were down 16.9% during mid-day trading on Monday .The stock traded as low as $1.13 and last traded at $1.18. Approximately ...

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine ...

Pasithea Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation ...

SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT’s) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea ...